The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
β-blockers-Global Market Insights and Sales Trends 2025
Synopsis
β-blockers are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack (myocardial infarction) after a first heart attack (secondary prevention). They are also widely used to treat high blood pressure (hypertension), although they are no longer the first choice for initial treatment of most patients.
The global β-blockers market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of β-blockers in various end use industries. The expanding demands from the Abnormal Heart Rhythms and Hypertension, are propelling β-blockers market. Nonselective Agents, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Selective Agents segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for β-blockers market, driven by demand from China, the second largest economy with some signs of stabilising, the β-blockers market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for β-blockers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global β-blockers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global β-blockers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, β-blockers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of β-blockers covered in this report include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc.
The global β-blockers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Global β-blockers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global β-blockers market, Segment by Type:
Nonselective Agents
Selective Agents
Global β-blockers market, by Application
Abnormal Heart Rhythms
Hypertension
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of β-blockers manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of β-blockers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
β-blockers are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack (myocardial infarction) after a first heart attack (secondary prevention). They are also widely used to treat high blood pressure (hypertension), although they are no longer the first choice for initial treatment of most patients.
The global β-blockers market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of β-blockers in various end use industries. The expanding demands from the Abnormal Heart Rhythms and Hypertension, are propelling β-blockers market. Nonselective Agents, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Selective Agents segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for β-blockers market, driven by demand from China, the second largest economy with some signs of stabilising, the β-blockers market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for β-blockers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global β-blockers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global β-blockers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, β-blockers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of β-blockers covered in this report include Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc.
The global β-blockers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Global β-blockers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global β-blockers market, Segment by Type:
Nonselective Agents
Selective Agents
Global β-blockers market, by Application
Abnormal Heart Rhythms
Hypertension
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of β-blockers manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of β-blockers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 β-blockers Market Overview
1.1 β-blockers Product Overview
1.2 β-blockers Market Segment by Type
1.2.1 Nonselective Agents
1.2.2 Selective Agents
1.3 Global β-blockers Market Size by Type
1.3.1 Global β-blockers Market Size Overview by Type (2018-2029)
1.3.2 Global β-blockers Historic Market Size Review by Type (2018-2023)
1.3.3 Global β-blockers Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America β-blockers Sales Breakdown by Type (2018-2023)
1.4.2 Europe β-blockers Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific β-blockers Sales Breakdown by Type (2018-2023)
1.4.4 Latin America β-blockers Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa β-blockers Sales Breakdown by Type (2018-2023)
2 Global β-blockers Market Competition by Company
2.1 Global Top Players by β-blockers Sales (2018-2023)
2.2 Global Top Players by β-blockers Revenue (2018-2023)
2.3 Global Top Players by β-blockers Price (2018-2023)
2.4 Global Top Manufacturers β-blockers Manufacturing Base Distribution, Sales Area, Product Type
2.5 β-blockers Market Competitive Situation and Trends
2.5.1 β-blockers Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by β-blockers Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in β-blockers as of 2022)
2.7 Date of Key Manufacturers Enter into β-blockers Market
2.8 Key Manufacturers β-blockers Product Offered
2.9 Mergers & Acquisitions, Expansion
3 β-blockers Status and Outlook by Region
3.1 Global β-blockers Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global β-blockers Historic Market Size by Region
3.2.1 Global β-blockers Sales in Volume by Region (2018-2023)
3.2.2 Global β-blockers Sales in Value by Region (2018-2023)
3.2.3 Global β-blockers Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global β-blockers Forecasted Market Size by Region
3.3.1 Global β-blockers Sales in Volume by Region (2024-2029)
3.3.2 Global β-blockers Sales in Value by Region (2024-2029)
3.3.3 Global β-blockers Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global β-blockers by Application
4.1 β-blockers Market Segment by Application
4.1.1 Abnormal Heart Rhythms
4.1.2 Hypertension
4.2 Global β-blockers Market Size by Application
4.2.1 Global β-blockers Market Size Overview by Application (2018-2029)
4.2.2 Global β-blockers Historic Market Size Review by Application (2018-2023)
4.2.3 Global β-blockers Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America β-blockers Sales Breakdown by Application (2018-2023)
4.3.2 Europe β-blockers Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific β-blockers Sales Breakdown by Application (2018-2023)
4.3.4 Latin America β-blockers Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa β-blockers Sales Breakdown by Application (2018-2023)
5 North America β-blockers by Country
5.1 North America β-blockers Historic Market Size by Country
5.1.1 North America β-blockers Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America β-blockers Sales in Volume by Country (2018-2023)
5.1.3 North America β-blockers Sales in Value by Country (2018-2023)
5.2 North America β-blockers Forecasted Market Size by Country
5.2.1 North America β-blockers Sales in Volume by Country (2024-2029)
5.2.2 North America β-blockers Sales in Value by Country (2024-2029)
6 Europe β-blockers by Country
6.1 Europe β-blockers Historic Market Size by Country
6.1.1 Europe β-blockers Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe β-blockers Sales in Volume by Country (2018-2023)
6.1.3 Europe β-blockers Sales in Value by Country (2018-2023)
6.2 Europe β-blockers Forecasted Market Size by Country
6.2.1 Europe β-blockers Sales in Volume by Country (2024-2029)
6.2.2 Europe β-blockers Sales in Value by Country (2024-2029)
7 Asia-Pacific β-blockers by Region
7.1 Asia-Pacific β-blockers Historic Market Size by Region
7.1.1 Asia-Pacific β-blockers Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific β-blockers Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific β-blockers Sales in Value by Region (2018-2023)
7.2 Asia-Pacific β-blockers Forecasted Market Size by Region
7.2.1 Asia-Pacific β-blockers Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific β-blockers Sales in Value by Region (2024-2029)
8 Latin America β-blockers by Country
8.1 Latin America β-blockers Historic Market Size by Country
8.1.1 Latin America β-blockers Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America β-blockers Sales in Volume by Country (2018-2023)
8.1.3 Latin America β-blockers Sales in Value by Country (2018-2023)
8.2 Latin America β-blockers Forecasted Market Size by Country
8.2.1 Latin America β-blockers Sales in Volume by Country (2024-2029)
8.2.2 Latin America β-blockers Sales in Value by Country (2024-2029)
9 Middle East and Africa β-blockers by Country
9.1 Middle East and Africa β-blockers Historic Market Size by Country
9.1.1 Middle East and Africa β-blockers Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa β-blockers Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa β-blockers Sales in Value by Country (2018-2023)
9.2 Middle East and Africa β-blockers Forecasted Market Size by Country
9.2.1 Middle East and Africa β-blockers Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa β-blockers Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer β-blockers Products Offered
10.1.5 Pfizer Recent Development
10.2 Novartis
10.2.1 Novartis Company Information
10.2.2 Novartis Introduction and Business Overview
10.2.3 Novartis β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Novartis β-blockers Products Offered
10.2.5 Novartis Recent Development
10.3 Merck
10.3.1 Merck Company Information
10.3.2 Merck Introduction and Business Overview
10.3.3 Merck β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Merck β-blockers Products Offered
10.3.5 Merck Recent Development
10.4 Astra Zeneca
10.4.1 Astra Zeneca Company Information
10.4.2 Astra Zeneca Introduction and Business Overview
10.4.3 Astra Zeneca β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Astra Zeneca β-blockers Products Offered
10.4.5 Astra Zeneca Recent Development
10.5 Jhonson and Johnson
10.5.1 Jhonson and Johnson Company Information
10.5.2 Jhonson and Johnson Introduction and Business Overview
10.5.3 Jhonson and Johnson β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Jhonson and Johnson β-blockers Products Offered
10.5.5 Jhonson and Johnson Recent Development
10.6 Eli Lilly
10.6.1 Eli Lilly Company Information
10.6.2 Eli Lilly Introduction and Business Overview
10.6.3 Eli Lilly β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Eli Lilly β-blockers Products Offered
10.6.5 Eli Lilly Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Information
10.7.2 Sanofi Introduction and Business Overview
10.7.3 Sanofi β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Sanofi β-blockers Products Offered
10.7.5 Sanofi Recent Development
10.8 Bristol-Myers Squibb
10.8.1 Bristol-Myers Squibb Company Information
10.8.2 Bristol-Myers Squibb Introduction and Business Overview
10.8.3 Bristol-Myers Squibb β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Bristol-Myers Squibb β-blockers Products Offered
10.8.5 Bristol-Myers Squibb Recent Development
10.9 Bayer
10.9.1 Bayer Company Information
10.9.2 Bayer Introduction and Business Overview
10.9.3 Bayer β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Bayer β-blockers Products Offered
10.9.5 Bayer Recent Development
10.10 GSK
10.10.1 GSK Company Information
10.10.2 GSK Introduction and Business Overview
10.10.3 GSK β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.10.4 GSK β-blockers Products Offered
10.10.5 GSK Recent Development
10.11 Teva Pharmaceutical
10.11.1 Teva Pharmaceutical Company Information
10.11.2 Teva Pharmaceutical Introduction and Business Overview
10.11.3 Teva Pharmaceutical β-blockers Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Teva Pharmaceutical β-blockers Products Offered
10.11.5 Teva Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 β-blockers Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 β-blockers Industrial Chain Analysis
11.4 β-blockers Market Dynamics
11.4.1 β-blockers Industry Trends
11.4.2 β-blockers Market Drivers
11.4.3 β-blockers Market Challenges
11.4.4 β-blockers Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 β-blockers Distributors
12.3 β-blockers Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
